Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone

NCT06865365 on ClinicalTrials.gov · last registry update 2025-03-21

Registered but not yet open, with 72 participants planned. Due to report 1 February 2027, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: % total weight loss. Sponsors move these dates routinely; any movement since this site started watching is listed below. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Medical University of Vienna
Sponsor type: Other
Enrollment: 72
Started: 2025-05-01
Primary completion: 2027-02-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

% total weight loss

Conditions studied

Obesity, Adolescent

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.